Pasireotide's FDA Approval Status
Pasireotide holds full FDA approval in the United States, marking it as a legitimate, legal pharmaceutical for specific therapeutic indications. The drug is marketed under the brand name Signifor and is available in two formulation types: an intramuscular long-acting release (LAR) injection and a subcutaneous immediate-release injection.
The FDA approved Signifor (pasireotide) in December 2012 for acromegaly in patients who cannot be adequately controlled by surgery or somatostatin analogues. In 2014, the FDA expanded its approval to include Cushing's disease in patients for whom pituitary surgery is not an option or has failed. These approvals are permanent and remain in effect today, making pasireotide one of the few peptide-based therapeutics with unequivocal legal status across the United States.
Because pasireotide is FDA-approved, it falls under Schedule X of the Controlled Substances Act—meaning it's not a controlled substance. It can be legally dispensed by any licensed pharmacy with a valid prescription from a licensed healthcare provider.
Regulatory History and Clinical Evidence
The path to FDA approval was rigorous. Pasireotide underwent extensive clinical development involving 71 clinical trials globally, with pivotal trials in the US demonstrating its efficacy and safety profile in both acromegaly and Cushing's disease.
For acromegaly, the pivotal Phase III trial (PASIOCREM) showed that pasireotide LAR significantly reduced growth hormone levels in patients who had failed standard treatments. A study published in The Lancet demonstrated that 40% of acromegaly patients achieved normal growth hormone levels with pasireotide, compared to much lower success rates with alternative therapies.
For Cushing's disease, the PAS-301 trial demonstrated that pasireotide normalized urinary free cortisol in approximately 26% of treatment-naive patients and 17% of previously treated patients—a meaningful improvement for a rare and dangerous condition.
These trials established the evidence base that convinced the FDA to grant approval. The regulatory approval pathway for pasireotide involved:
- Preclinical testing to establish biological mechanism and toxicology
- Investigational New Drug (IND) application to enable human studies
- Phase I, II, and III clinical trials involving thousands of patients
- New Drug Application (NDA) submission with comprehensive safety and efficacy data
- FDA review and approval based on the risk-benefit profile
This multi-year, multi-stage process is why FDA-approved compounds differ fundamentally from unapproved research peptides.
Legal Access and Prescribing Requirements
Because pasireotide is FDA-approved, accessing it legally in the US is straightforward in principle: you need a prescription from a licensed physician (MD, DO, or NP/PA with prescriptive authority) who has diagnosed you with acromegaly or Cushing's disease.
Here's what consumers should know:
Insurance and Cost: Pasireotide is typically covered by major insurance plans when prescribed for its approved indications, though coverage may require prior authorization. Out-of-pocket costs vary widely but can be significant; some patient assistance programs exist through the manufacturer to help offset expenses.
Pharmacy Access: Any licensed pharmacy—retail, mail-order, or specialty—can dispense pasireotide with a valid prescription. There are no special restrictions or licensing requirements for pharmacies beyond standard pharmaceutical regulations.
Prescriber Qualifications: Any licensed physician can prescribe pasireotide, though endocrinologists specializing in pituitary disorders typically manage long-term therapy. Your doctor must document the diagnosis and confirm that you meet FDA-approved indications (acromegaly or Cushing's disease).
Off-label Use: Physicians may legally prescribe pasireotide off-label for other conditions (e.g., neuroendocrine tumors), though this falls outside FDA approval and may have different insurance coverage implications.
Enforcement and Regulatory Oversight
The FDA maintains ongoing oversight of pasireotide through several mechanisms:
Post-market Surveillance: Manufacturers must report adverse events to the FDA. Patients and healthcare providers can also file reports directly via MedWatch, the FDA's adverse event reporting system.
Manufacturing Standards: Pasireotide is manufactured under Current Good Manufacturing Practice (cGMP) standards, meaning production facilities are regularly inspected and must meet stringent quality controls.
Labeling and Warnings: The FDA-approved prescribing information includes boxed warnings about gallstones (cholelithiasis) and hyperglycemia, which are known risks. Prescribers and patients should be aware of these before initiating therapy.
Drug Interactions and Contraindications: The approved label specifies drug interactions (e.g., with CYP3A4 inhibitors) and contraindications. Physicians must screen for these before prescribing.
If a pasireotide product is found to be counterfeit, subpotent, or otherwise non-compliant, the FDA has enforcement authority to issue recalls, warning letters, and initiate legal action against violators.
How Pasireotide Differs from Unapproved Peptides
A critical distinction: pasireotide's FDA approval is fundamentally different from peptides marketed as "research compounds" or "not for human consumption." Here's why:
Approved compounds like pasireotide have:
- Demonstrated safety and efficacy in human clinical trials
- FDA oversight of manufacturing, labeling, and adverse event reporting
- Legal prescribing pathways through licensed providers
- Insurance coverage options
- Liability protections for manufacturers
Unapproved or research compounds lack these safeguards. They're sold without evidence of human efficacy, minimal quality oversight, and no legal recourse if contaminated or ineffective.
Pasireotide's legal status in the US reflects completion of the gold-standard regulatory pathway. This is not a grey area—it's a fully legitimized pharmaceutical.
Comparing US Status to Other Jurisdictions
Pasireotide's legal standing extends beyond the US. The European Medicines Agency (EMA) authorised Signifor in 2012, and Health Canada approved it as well, making it a truly global pharmaceutical with harmonized regulatory recognition.
This consistency across major regulatory bodies reinforces the robustness of pasireotide's safety and efficacy profile.
What Consumers Should Know
1. Pasireotide is legal and widely available in the US when prescribed for approved indications by a licensed physician.
2. It requires a diagnosis and ongoing medical supervision. You cannot self-diagnose acromegaly or Cushing's disease—these conditions require specialist evaluation and testing.
3. Side effects are manageable but significant. The most common issues are gallstones and elevated blood glucose. Your doctor will monitor you regularly with imaging and lab work.
4. Genetic or brand considerations matter. Pasireotide is available as a brand-name product (Signifor) and generic equivalents. The FDA requires generics to be bioequivalent to the brand, but discuss any formulation changes with your doctor.
5. Cost and access challenges exist. While legal, pasireotide can be expensive. Patient advocacy groups and manufacturer assistance programs can help if cost is a barrier.
6. Avoid counterfeit sources. Because pasireotide is valuable and FDA-approved, it's occasionally targeted by counterfeiters. Buy only from licensed pharmacies you trust.
For more information on pasireotide's mechanism, see our deep dives on somatostatin receptor ligands and related compounds like octreotide and lanreotide.